|Day Low/High||23.53 / 26.16|
|52 Wk Low/High||4.04 / 32.18|
A fresh look at all 17 ideas: the winners, the losers and the still to be determined.
I don't think MGNX has quite the same upside as IFRX, but a push above $23.50 should spur buying.
MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.